Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
GLENMARK Stock Analysis
Views
Red Flags
Positive
Strong price momentum
Analysts have been raising forward EPS estimates
Moderate ROE but improving trend
High and improving operating margin
Strong revenue growth and above median growth of industry
Low Debt to Equity, not much change from last year
Consistently pays dividend
Company is net cash
Negative
Expensive and at a premium to industry median P/E
Company's earnings are of low quality
Low dividend yield
Neutral
Not enough talking point with neutral stance
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
GLENMARK Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
GLENMARK Bulk, Block & Insider Trades
GLENMARK Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Stock split
Bonus(1 new shares for 1 existing shares)Bonus issue of 59308570 securities Ex-date: 4th Mar 2005 Announced on: 7th Jan 2005
Stock split(1 : 2)Nominal value change from Rs. 2 to Rs. 1 Ex-date: 10th Sep 2007 Announced on: 11th Jun 2007
Stock split(1 : 5)Nominal value change from Rs. 10 to Rs. 2 Ex-date: 23rd Oct 2003 Announced on: 11th Aug 2003
Company Profile
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company al... Read More
Key personnel
Mr. Glenn Mario SaldanhaD
Executive Chairman of the Board, Managing Director
Mr. Anurag MantriD
Global Chief Financial Officer, Executive Director
Mr. Harish Vinayak Kuber
Compliance Officer, Company Secretary
Mrs. Cherylann (Cheryl) PintoD
Executive Director - Corporate Services
Mrs. Blanche E. SaldanhaD
Non-Executive Director
Ms. Patricia AndrewsD
Additional Non-Executive Independent Director
Mr. Dipankar BhattacharjeeD
Non-Executive Independent Director
Mrs. Vijayalakshmi Rajaram IyerD
Non-Executive Independent Director
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Glenmark Pharmaceuticals Ltd.?
The current share price of Glenmark Pharmaceuticals Ltd. is ₹ 2,007.05 as of 09 Jan 2026.
What is the PE ratio of Glenmark Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd. is 56.09 as of the latest financial data.
What is the ROE and ROCE of Glenmark Pharmaceuticals Ltd.?
Glenmark Pharmaceuticals Ltd. has a Return on Equity (ROE) of 11.20% and a Return on Capital Employed (ROCE) of 34.06% as per the latest financial reports.
What is the market cap of Glenmark Pharmaceuticals Ltd.?
The market capitalization of Glenmark Pharmaceuticals Ltd. stands at ₹ 56,639.20 Cr.
What is the dividend yield of Glenmark Pharmaceuticals Ltd.?
The dividend yield of Glenmark Pharmaceuticals Ltd. is 0.25% based on the current market price.
What is the RSI of Glenmark Pharmaceuticals Ltd.?
The Relative Strength Index (RSI) of Glenmark Pharmaceuticals Ltd. is 49.95.
What is the FII and DII holding in Glenmark Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 20.73% and Domestic Institutional Investors (DII) hold 16.99% of Glenmark Pharmaceuticals Ltd. shares.
What sector does Glenmark Pharmaceuticals Ltd. belong to?
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector.
What is the beta of Glenmark Pharmaceuticals Ltd. stock?
The beta of Glenmark Pharmaceuticals Ltd. stock is 0.59, indicating its volatility relative to the broader market.
